268 related articles for article (PubMed ID: 26679005)
1. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
2. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
[TBL] [Abstract][Full Text] [Related]
3. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha SH; Kim K; Song YK
Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
[TBL] [Abstract][Full Text] [Related]
5. Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib.
Lee WJ; Lee JH; Won CH; Chang SE; Choi JH; Moon KC; Kang YK; Lee MW
Int J Dermatol; 2016 May; 55(5):e268-74. PubMed ID: 26680344
[TBL] [Abstract][Full Text] [Related]
6. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
8. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Brouard MC; Prins C; Mach-Pascual S; Saurat JH
Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
10. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia.
Scott AD; Lee M; Kubba F; Chu A
Clin Exp Dermatol; 2015 Dec; 40(8):926-7. PubMed ID: 25266712
[No Abstract] [Full Text] [Related]
11. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
[TBL] [Abstract][Full Text] [Related]
12. Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Paolino G; Didona D; Clerico R; Corsetti P; Ambrifi M; Bottoni U; Calvieri S
Cutis; 2016 Jun; 97(6):E12-6. PubMed ID: 27416091
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate-induced lichenoid drug eruption.
Penn EH; Chung HJ; Keller M
Cutis; 2017 Mar; 99(3):189-192. PubMed ID: 28398413
[TBL] [Abstract][Full Text] [Related]
14. Imatinib Mesylate Induced Erythroderma.
Lunge S; Bhise R
J Assoc Physicians India; 2018 Dec; 66(12):79-80. PubMed ID: 31313559
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate-induced pseudoporphyria in two children.
Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
17. A patient of chronic myelogenous leukemia developing painful rash on feet.
Kumar P; Das NK; Sil A; Chakrabarti P
J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
[No Abstract] [Full Text] [Related]
18. Cystic acne due to imatinib therapy for chronic myelocytic leukemia.
Hwang A; Iskandar A; Del Rosario M; Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):972-974. PubMed ID: 29498323
[TBL] [Abstract][Full Text] [Related]
19. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
20. Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy.
Ćojbašić I; Mačukanović-Golubović L; Vučić M; Tijanić I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):696-702. PubMed ID: 28712742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]